Wall Street Zen upgraded shares of Agenus (NASDAQ:AGEN - Free Report) from a strong sell rating to a hold rating in a research note issued to investors on Thursday.
A number of other brokerages also recently weighed in on AGEN. Robert W. Baird upped their price objective on shares of Agenus from $3.00 to $4.00 and gave the stock a "neutral" rating in a research report on Tuesday, May 13th. B. Riley restated a "buy" rating on shares of Agenus in a research note on Monday, April 21st. Finally, HC Wainwright reiterated a "neutral" rating on shares of Agenus in a research report on Tuesday, May 13th. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $9.00.
Check Out Our Latest Research Report on Agenus
Agenus Price Performance
NASDAQ:AGEN traded down $0.16 during trading hours on Thursday, reaching $3.66. The company had a trading volume of 456,541 shares, compared to its average volume of 563,915. Agenus has a 1-year low of $1.38 and a 1-year high of $19.69. The business's 50 day moving average price is $2.48 and its 200-day moving average price is $2.87. The firm has a market cap of $100.40 million, a PE ratio of -0.33 and a beta of 1.48.
Agenus (NASDAQ:AGEN - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.61) by $0.58. The firm had revenue of $24.07 million for the quarter, compared to analysts' expectations of $26.38 million. On average, analysts expect that Agenus will post -12.55 earnings per share for the current fiscal year.
Institutional Trading of Agenus
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Corton Capital Inc. purchased a new position in Agenus in the 4th quarter valued at about $36,000. Apollon Wealth Management LLC raised its holdings in shares of Agenus by 25.0% during the first quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock valued at $38,000 after acquiring an additional 5,000 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Agenus in the fourth quarter valued at approximately $51,000. Acadian Asset Management LLC purchased a new position in shares of Agenus in the first quarter valued at approximately $58,000. Finally, Bank of Montreal Can acquired a new stake in shares of Agenus in the fourth quarter worth approximately $69,000. Hedge funds and other institutional investors own 61.46% of the company's stock.
About Agenus
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Stories
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
